![]() ![]() Both the oral and intravenous formulations of the drug combination are well tolerated. In clinical trials, high proportions of patients who received netupitant/palonosetron (used in combination with the corticosteroid dexamethasone) prior to chemotherapy reported no vomiting, no requirement for rescue medication, and no significant nausea in the 5 days post chemotherapy. Approved for use in the prevention of acute and delayed CINV in adults, netupitant/palonosetron is given orally or via intravenous infusion as a single dose prior to chemotherapy. Netupitant/palonosetron (NEPA Akynzeo ®) is a fixed-dose combination of two drugs (netupitant, a neurokinin 1 receptor antagonist and palonosetron, a serotonin 3 receptor antagonist) which target two different signalling pathways involved in the induction of vomiting. The fixed-dose combination is concordant with guideline recommendations and provides a simple and convenient option for prophylaxis against acute and delayed CINV in patients receiving highly or moderately emetogenic chemotherapy.Ĭhemotherapy-induced nausea and vomiting (CINV) is a common problem during cancer treatment. Both the oral and IV formulations of the drug combination are well tolerated. Further, oral netupitant/palonosetron was found to be superior to palonosetron and non-inferior to aprepitant plus granisetron in preventing CINV in individual trials. In clinical trials, (fos)netupitant/palonosetron plus dexamethasone was associated with high complete response rates (no emesis and no rescue medication) in the acute, delayed and overall phases in patients receiving highly or moderately emetogenic chemotherapy, with efficacy maintained over multiple cycles. Administered as a single dose, (fos)netupitant/palonosetron (in combination with dexamethasone) is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. ![]() palonosetron (NEPA Akynzeo ®), available in oral and intravenous (IV) formulations, is a fixed-dose combination of the neurokinin 1 (NK1) receptor antagonist netupitant (or the prodrug, fosnetupitant, in the IV formulation) and the second-generation serotonin 3 (5-HT 3) receptor antagonist palonosetron. "Fosnetupitant and Palonosetron (Professional Patient Advice)"."Netupitant mixture with palonosetron".Archived from the original on 19 March 2020. ^ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection".^ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718".^ "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy".Vienna: Österreichischer Apothekerverlag. Archived from the original on 24 January 2020. ^ a b "Drug Trials Snapshots: Akynzeo".Archived (PDF) from the original on 26 June 2016. ^ "Akynzeo: Summary of Product Characteristics" (PDF).Archived from the original on 1 February 2017. ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release).Archived from the original on 18 October 2020. ^ a b c d "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection".^ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)".: CS1 maint: archived copy as title ( link) Archived (PDF) from the original on 10 June 2022. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015".Archived from the original on 9 September 2017. Therapeutic Goods Administration (TGA) (Report). ^ AusPAR: Netupitant / Palonosetron (as hydrochloride).Archived from the original on 19 December 2019. ^ a b "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |